• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

COVID-19 Treatment and Vaccine Tracker Identifies New Treatments & Vaccines in Development

by Jasmine Pennic 03/30/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
COVID-19 Treatment and Vaccine Tracker Identifies New Treatments & Vaccines in Development

What You Should Know:

– The Milken Institute launched an effort to track and disseminate accurate information about COVID-19 treatments and vaccines in development.

– Since launch, more than two dozen new candidates have been identified, with some progressing toward clinical trials.


The Milken Institute COVID-19 Treatment and Vaccine Tracker has identified 16 new treatments in the pipeline along with nine new vaccine candidates since launching one week ago. Two potential vaccines have advanced to clinical trials. They are being developed by Moderna, Inc. and CanSino Biologics. In addition, the World Health Organization announced the global SOLIDARITY trial to develop treatments for the disease.

In total, the Milken Institute is now tracking 71 treatments and 47 vaccines in development. Treatments are grouped into candidate categories, including antibodies, antivirals, cell-based therapies, among others.

The tracker was updated to include more detail, including FDA-approved indications, clinical trials ongoing for other diseases, timing, as well as for vaccines, related uses, such as whether the same platform was used to create other vaccines and for which pathogens. In coming days, the tracker will include expanded information about clinical trials and the results for each candidate.

The COVID-19 Treatment and Vaccine Tracker is produced and maintained by FasterCures, a center of the Milken Institute, with an Advisory Council comprised of three former FDA chiefs, a Nobel Laureate biologist, and key industry leaders.

“We are continuing to see a full-court press from the biomedical research and development community to find a solution to the COVID-19 pandemic,” said Esther Krofah, executive director of FasterCures. “I am more hopeful than ever that there will be a surge of treatment and vaccine candidates making their way into clinical trials, and into the hands of patients.”

The Milken Institute COVID-19 vaccine development and treatment tracker is compiled from publicly available sources. The information in the tracker is updated regularly. 

The Milken Institute welcomes input on new vaccines and treatments in development. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |